Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 418

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study

Open access
Deepak, Parakkal, Kim, Wooseob, Paley, Michael A., Yang, Monica, Carvidi, Alexander B., Demissie, Emanuel G., El-Qunni, Alia A., Haile, Alem, Huang, Katherine, Kinnett, Baylee, Liebeskind, Mariel J., Liu, Zhuoming, McMorrow, Lily E., Paez, Diana, Pawar, Niti, Perantie, Dana C., Schriefer, Rebecca E., Sides, Shannon E., Thapa, Mahima, Gergely, Maté, Abushamma, Suha, Akuse, Sewuese, Klebert, Michael, Mitchell, Lynne, Nix, Darren, Graf, Jonathan, Taylor, Kimberly E., Chahin, Salim, Ciorba, Matthew A., Katz, Patricia, Matloubian, Mehrdad, O’Halloran, Jane A., Presti, Rachel M., Wu, Gregory F., Whelan, Sean P.J., Buchser, William J., Gensler, Lianne S., Nakamura, Mary C., Ellebedy, Ali H., Kim, Alfred H.J.·2021·Annals of Internal Medicine

Abstract

BACKGROUND: Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2 vaccination platforms provide robust protection in immunocompetent individuals, the immunogenicity in CID patients on immunosuppression is not well established. Therefore, determining the effectiveness of SARS-CoV-2 vaccines in the setting of immunosuppression is essential to risk-stratify CID patients with impaired protection and provide clinical guidance regarding medication management. METHODS: binding, neutralizing antibody titers, and circulating S-specific plasmablasts were quantified to assess the magnitude and quality of the humoral response following vaccination. RESULTS: Compared to immunocompetent controls, a three-fold reduction in anti-S IgG titers (P=0.009) and SARS-CoV-2 neutralization (p<0.0001) were observed in CID patients. B cell depletion and glucocorticoids exerted the strongest effect with a 36- and 10-fold reduction in humoral responses, respectively (p<0.0001). Janus kinase inhibitors and antimetabolites, including methotrexate, also blunted antibody titers in multivariate regression analysis (P<0.0001, P=0.0023, respectively). Other targeted therapies, such as TNF inhibitors, IL-12/23 inhibitors, and integrin inhibitors, had only modest impacts on antibody formation and neutralization. CONCLUSIONS: CID patients treated with immunosuppressive therapies exhibit impaired SARS-CoV-2 vaccine-induced immunity, with glucocorticoids and B cell depletion therapy more severely impeding optimal responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/m21-1757

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 418

Metadata

Authors
Deepak, P., Kim, W., Paley, M. A., Yang, M., Carvidi, A. B., Demissie, E. G., El-Qunni, A. A., Haile, A., Huang, K., Kinnett, B., Liebeskind, M. J., Liu, Z., McMorrow, L. E., Paez, D., Pawar, N., Perantie, D. C., Schriefer, R. E., Sides, S. E., Thapa, M., Gergely, M., Abushamma, S., Akuse, S., Klebert, M., Mitchell, L., Nix, D., Graf, J., Taylor, K. E., Chahin, S., Ciorba, M. A., Katz, P., Matloubian, M., O’Halloran, J. A., Presti, R. M., Wu, G. F., Whelan, S. P. J., Buchser, W. J., Gensler, L. S., Nakamura, M. C., Ellebedy, A. H., & Kim, A. H. J.
Venue
Annals of Internal Medicine
Published
2021-11
Volume
174
Issue
11
Pages
1572-1585
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W3197081215
Cited by
418
References
55
FWCI
28.21
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study. https://app.cochat.ai/papers/10.7326/m21-1757
The paper
Deepak, P., Kim, W., Paley, M. A., Yang, M., Carvidi, A. B., Demissie, E. G., El-Qunni, A. A., Haile, A., Huang, K., Kinnett, B., Liebeskind, M. J., Liu, Z., McMorrow, L. E., Paez, D., Pawar, N., Perantie, D. C., Schriefer, R. E., Sides, S. E., Thapa, M., . . . Kim, A. H. J. (2021). Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study. Annals of Internal Medicine. https://doi.org/10.7326/m21-1757

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.